ADA 2020: Tandem Wins FDA Nod For T:Slim Pump Technology In Children; Positive Feedback on Studies
After announcing positive results at the American Diabetes Association conference and an expanded FDA approval for its insulin pump delivery system, Tandem Diabetes Care’s CEO outlines its path forward.
You may also be interested in...
Three major insulin pump developers are gearing up to introduce next-generation devices over the coming year, but COVID-19 continues to create uncertainties.
Tandem Diabetes Care and Medtronic have signed a patent cross-license agreement that paves the way for joint development of future diabetes products and services while avoiding potential legal disagreements.
Dexcom’s CEO explained the company’s strategy for continued growth, including marketing opportunities for its G6 and G6 Pro continuous glucose monitors and plans for the next-gen G7 CGM.